Literature DB >> 22035113

The yin and yang of chemokine receptor activation.

Graeme O'Boyle1.   

Abstract

Chemokines represent a class of cytokines that control the migration of leucocytes. The human chemokine system comprises 44 ligands and 21 receptors that have evolved to control leucocyte migration. Although chemokines are an attractive therapeutic target for anti-inflammatory intervention, clinical trials of small molecule receptor antagonists have failed to demonstrate efficacy. One often cited explanation for this is the apparent redundancy within the chemokine system, wherein several ligands bind and activate each receptor. The work of Scholten et al. and Nedjai et al. reported in this issue of the British Journal of Pharmacology demonstrates that this redundancy does not exist at the molecular level and provides a powerful insight into the complex nature of chemokine receptor activation.
© 2011 The Author. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22035113      PMCID: PMC3417416          DOI: 10.1111/j.1476-5381.2011.01759.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

Review 1.  Anti-chemokine small molecule drugs: a promising future?

Authors:  Amanda E I Proudfoot; Christine A Power; Matthias K Schwarz
Journal:  Expert Opin Investig Drugs       Date:  2010-03       Impact factor: 6.206

2.  Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.

Authors:  D Eastwood; L Findlay; S Poole; C Bird; M Wadhwa; M Moore; C Burns; R Thorpe; R Stebbings
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 3.  The attraction of chemokines as a target for specific anti-inflammatory therapy.

Authors:  James E Pease; Timothy J Williams
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.

Authors:  D J Scholten; M Canals; M Wijtmans; S de Munnik; P Nguyen; D Verzijl; I J P de Esch; H F Vischer; M J Smit; R Leurs
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

5.  Primate testing of TGN1412: right target, wrong cell.

Authors:  M Pallardy; T Hünig
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

6.  Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2.

Authors:  Graeme O'Boyle; John G Brain; John A Kirby; Simi Ali
Journal:  Mol Immunol       Date:  2006-11-01       Impact factor: 4.407

Review 7.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

8.  The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice.

Authors:  Ronald P Gladue; Susan H Cole; Marsha L Roach; Laurie A Tylaska; Robin T Nelson; Richard M Shepard; John D McNeish; Kevin T Ogborne; Kuldeep S Neote
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

9.  Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.

Authors:  Belinda Nedjai; Hubert Li; Ilana L Stroke; Emma L Wise; Maria L Webb; J Robert Merritt; Ian Henderson; Anthony E Klon; Andrew G Cole; Richard Horuk; Nagarajan Vaidehi; James E Pease
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

10.  T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor.

Authors:  Peter Newton; Graeme O'Boyle; Yvonne Jenkins; Simi Ali; John A Kirby
Journal:  Mol Immunol       Date:  2009-09-20       Impact factor: 4.407

View more
  1 in total

Review 1.  Understanding the mechanisms that facilitate specificity, not redundancy, of chemokine-mediated leukocyte recruitment.

Authors:  Douglas P Dyer
Journal:  Immunology       Date:  2020-05-06       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.